CLINICAL TRIALS PROFILE FOR LOTENSIN
✉ Email this page to a colleague
All Clinical Trials for LOTENSIN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00630708 ↗ | Safety of Dual Blockage of Rennin-angiotensin System in Patients With Advanced Renal Insufficiency | Terminated | Nanfang Hospital of Southern Medical University | N/A | 2008-02-01 | The primary aim of the present study is to assess the safety of combined treatment of benazepril (an ACE inhibitor) or losartan (an ARB) in non-diabetic patients with advanced renal insufficiency. |
| NCT00649038 ↗ | Fed Study of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Lotensin HCT® Tablets 20 mg/25 mg | Completed | Mylan Pharmaceuticals | Phase 1 | 2002-12-01 | The objective of this study was to investigate the bioequivalence of Mylan benazepril HCl and hydrochlorothiazide 20 mg/25 mg to Novartis Lotensin HCT® 20 mg/25 mg combination tablets following a single, oral 40 mg/50 mg (2 x 20 mg/25 mg) dose administration under fed conditions. |
| NCT00649597 ↗ | Fasting Study of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Lotensin HCT® Tablets 20 mg/25 mg | Completed | Mylan Pharmaceuticals | Phase 1 | 2002-11-01 | The objective of this study was to investigate the bioequivalence of Mylan benazepril HCl and hydrochlorothiazide 20 mg/25 mg to Novartis Lotensin HCT® 20 mg/25 mg combination tablets following a single, oral 40 mg/50 mg (2 x 20 mg/25 mg) dose administration under fasting conditions. |
| NCT00836537 ↗ | Benazepril HCl 40 mg Tablets, Fed | Completed | Teva Pharmaceuticals USA | Phase 1 | 2001-03-01 | This study will compare the relative bioavailability (rate and extent of absorption) of 40 mg Benazepril Hydrochloride Tablets by TEVA Pharmaceuticals Industries, Ltd. with that of 40 mg LOTENSIN® Tablets by Novartis Pharmaceuticals following a single oral dose (1 x 40 mg) in healthy adult volunteers under non-fasting conditions. |
| NCT00836576 ↗ | Benazepril HCl 40 mg Tablets, Fasting | Completed | Teva Pharmaceuticals USA | Phase 1 | 2001-02-01 | The objective of this randomized, single-dose, two-way crossover evaluation is to compare the oral bioavailability of a test benazepril HCl formulation (TEVA Pharmaceutical Industries Ltd.) to an equivalent oral dose of the commercially available benazepril HCl (Lotensin®, Novartis Pharmaceuticals Corporation) in a test population of 40 adults under fasting conditions. |
| NCT00907374 ↗ | Low Dose Versus Aggressive Inhibition of the Renin-Angiotensin-Aldosterone (RAS) to Treat Microalbuminuria | Completed | Charles Drew University of Medicine and Science | N/A | 2005-07-01 | The objective of the study is to assess the effect of standard versus aggressive inhibition of the renin-angiotensin system (RAS)in type 2 diabetic patients with microalbuminuria (MA) on; a)progression of microalbuminuria, b)estimated glomerular filtration rate (eGFR), c)endothelial dysfunction (measured by post-hyperemia arterial tonometry) and d)the slowing of the progression of atherosclerotic disease (measured by carotid intima media thickness [CIMT]). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for LOTENSIN
Condition Name
Clinical Trial Locations for LOTENSIN
Trials by Country
Clinical Trial Progress for LOTENSIN
Clinical Trial Phase
Clinical Trial Sponsors for LOTENSIN
Sponsor Name
